Therapeutic options for patients with myelofibrosis in blast phase.
about
Practical management of patients with myelofibrosis receiving ruxolitinib.Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.Allogeneic stem cell transplantation for myelofibrosis in 2012.Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.Acute myeloid leukemia following a myeloproliferative neoplasm: clinical characteristics, genetic features and effects of therapy.Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches.Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortiumImpact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms.Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms.Novel Therapies for Myelofibrosis.Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis.Expression of CD markers in JAK2 positive myeloproliferative neoplasms: Prognostic significance
P2860
Q33410649-4DBB0128-C01B-4FAA-ACF7-90B5F3C6CF0AQ34752547-2300F4A4-E432-4494-BAB1-4449C1832D7FQ35552421-8401608C-DED3-408B-AB0E-F2B95F345946Q35988523-FBA74015-18DE-41AA-8204-CEDD447DC038Q36001930-AD06000F-70D1-4A5E-8926-C49F911FFDBEQ36708989-DCB2647B-410D-404F-A358-3EDBC157C6E4Q37998567-0FCED824-EA9D-4B98-9782-67DBAD0C6773Q38018908-FB57915B-BDF2-4BAC-AC55-C1390FC5619EQ38097735-51ADE650-D39D-4B32-AE48-EA243B4FB826Q38349213-32AAB1FE-DDA3-45A5-937B-536B4DA1FA06Q38429716-E3834989-5AC2-47C3-A34D-3BD09E8E98C9Q38844669-A3E4C1F3-F488-421F-A165-BDB793AF6A6FQ41084893-A0021472-88C5-4224-A602-768C34442B34Q42720284-4B85AB4F-34F2-4B39-89D9-A3B001C381CFQ42753989-F7BAE19F-C96B-44A1-BDF7-9B3454E12B26Q48284602-FB027650-85E8-4CAE-B5C4-AEF35B40684DQ52665839-5396FEC2-6FFE-41DC-BE0B-3685A468FF25Q52817185-A1217359-CCEC-4D89-8C26-1B4882C51BAEQ54349909-63A879EE-5693-4C7B-B767-53D21243628EQ58587352-EF74092F-9546-4A42-901E-EBA95AA9FBC6
P2860
Therapeutic options for patients with myelofibrosis in blast phase.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Therapeutic options for patients with myelofibrosis in blast phase.
@en
Therapeutic options for patients with myelofibrosis in blast phase.
@nl
type
label
Therapeutic options for patients with myelofibrosis in blast phase.
@en
Therapeutic options for patients with myelofibrosis in blast phase.
@nl
prefLabel
Therapeutic options for patients with myelofibrosis in blast phase.
@en
Therapeutic options for patients with myelofibrosis in blast phase.
@nl
P2093
P1433
P1476
Therapeutic options for patients with myelofibrosis in blast phase.
@en
P2093
Adriana Malone
Amy Rodriguez
John Mascarenhas
Ronald Hoffman
Shyamala Navada
Vesna Najfeld
P304
P356
10.1016/J.LEUKRES.2010.05.008
P577
2010-09-01T00:00:00Z